Trial results for AMAG iron replacement therapy favourable
The results from AMAG Pharmaceuticals’ four different Phase III trials for its ferumoxytol product demonstrated high efficacy and safety, with substantially higher mean increase in hemoglobin from base line to day 35. The overall adverse event rate was lower for patients on ferumoxytol, an IV iron replacement therapy, than for those on placebo.
- Grazax Phase III pediatric trial encouraging
- FDA approves Reyataz capsules for treating HIV-1 infection
- Novavax’s vaccine candidate works fine in trial’s second phase
- Iomai immunostimulant adjuvant patch trial positive
